We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
3 own
3 watching
Current Price
$5.89
$0.14
(2.43%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
151.95M
52-Week High
7.89
52-Week Low
2.28
Average Volume
0.03M
Dividend Yield
--
P/E Ratio
--
Market Capitalization151.95M
52-Week High7.89
52-Week Low2.28
Average Volume0.03M
Dividend Yield--
P/E Ratio--
What does the Stockal+Disclaimer.pdf do?
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 and LAVA-1278, which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.
Read More
News & Events about Stockal+Disclaimer.pdf.
Ticker Report
5days ago
LAVA Therapeutics (NASDAQ:LVTX Get Rating)s stock had its buy rating reiterated by equities research analysts at JMP Securities in a report released on Tuesday, Stock Target Advisor reports. They currently have a $6.00 price target on the stock. JMP Securities ...
Globe Newswire
26days ago
UTRECHT, The Netherlands and PHILADELPHIA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V.(Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today ...
Globe Newswire
1month ago
UTRECHT, The Netherlands and PHILADELPHIA, Oct. 07, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody platform of bispecific gamma delta T cell engagers, today announced the Company will present ...
PR Newswire
2 months ago
Thinking about buying stock in LAVA Therapeutics, Faraday Future Intelligent Electric, Melco Resorts & Entertainment, American Virtual Cloud Technologies, or Trip.com? Thinking about buying stock in LAVA Therapeutics, Faraday Future Intelligent Electric, Melco Resorts &amp...
Globe Newswire
2 months ago
Seagen to Develop and Commercialize LAVA-1223, a Bispecific T Cell Engager Designed to Target and Activate V9V2 (Gamma Delta) T Cells in the Presence of EGFR-Expressing Solid Tumors LAVA to Receive Upfront Payment of $50 Million, With Potential for Milestones of up to Approximately $650 Million and ...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$5.89
$0.14
(2.43%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00